Zacks Research Analysts Increase Earnings Estimates for BHC

Bausch Health Cos Inc. (NYSE:BHC) – Zacks Research upped their Q2 2026 earnings estimates for shares of Bausch Health Cos in a research report issued to clients and investors on Monday, June 23rd. Zacks Research analyst R. Department now expects that the company will earn $0.98 per share for the quarter, up from their prior forecast of $0.97. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Cos’ Q3 2026 earnings at $1.14 EPS, FY2026 earnings at $4.12 EPS and Q1 2027 earnings at $1.10 EPS.

BHC has been the subject of a number of other reports. Wall Street Zen downgraded Bausch Health Cos from a “buy” rating to a “hold” rating in a research note on Saturday, May 10th. Royal Bank Of Canada increased their target price on Bausch Health Cos from $8.50 to $10.00 and gave the stock a “sector perform” rating in a report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating and seven have given a hold rating to the stock. According to data from MarketBeat.com, Bausch Health Cos has a consensus rating of “Hold” and an average price target of $7.42.

Bausch Health Cos Stock Performance

BHC opened at $6.43 on Thursday. The company has a market capitalization of $2.38 billion, a P/E ratio of -58.41 and a beta of 0.28. The company has a 50-day moving average of $5.11 and a 200-day moving average of $6.31. Bausch Health Cos has a 1-year low of $3.96 and a 1-year high of $9.85.

Institutional Trading of Bausch Health Cos

Large investors have recently modified their holdings of the company. Toronto Dominion Bank increased its stake in shares of Bausch Health Cos by 1.0% in the fourth quarter. Toronto Dominion Bank now owns 167,212 shares of the company’s stock valued at $1,350,000 after purchasing an additional 1,712 shares during the period. Wells Fargo & Company MN grew its holdings in Bausch Health Cos by 7.9% in the 4th quarter. Wells Fargo & Company MN now owns 25,907 shares of the company’s stock worth $209,000 after buying an additional 1,896 shares in the last quarter. American Century Companies Inc. increased its position in Bausch Health Cos by 10.6% in the 4th quarter. American Century Companies Inc. now owns 27,236 shares of the company’s stock valued at $220,000 after acquiring an additional 2,600 shares during the period. Blair William & Co. IL raised its stake in Bausch Health Cos by 3.2% during the 4th quarter. Blair William & Co. IL now owns 84,707 shares of the company’s stock valued at $683,000 after acquiring an additional 2,622 shares in the last quarter. Finally, SBI Securities Co. Ltd. boosted its position in Bausch Health Cos by 244.2% during the 1st quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company’s stock worth $27,000 after acquiring an additional 3,001 shares during the period. Institutional investors and hedge funds own 78.65% of the company’s stock.

Insider Buying and Selling

In related news, Director John Paulson bought 3,564,059 shares of the company’s stock in a transaction on Friday, June 13th. The shares were purchased at an average cost of $5.94 per share, with a total value of $21,170,510.46. Following the completion of the transaction, the director now directly owns 32,791,702 shares of the company’s stock, valued at approximately $194,782,709.88. This represents a 12.19% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have acquired a total of 6,352,667 shares of company stock worth $35,870,767 over the last quarter. 8.05% of the stock is owned by company insiders.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.